Background Epidermal growth factor receptor (EGFR) is a validated target in squamous-cell
carcinoma of the head and neck, but in patients with recurrent or metastatic disease, EGFR …

5504 Background: We previously reported single agent activity for gefitinib in HNC (Cohen,
JCO, 2003). EGFR activation can upregulate vascular endothelial growth factor (VEGF) …

Purpose To determine the phase II dose and objective response rate of erlotinib, a selective
epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin in …

Purpose To determine the efficacy and safety profiles of erlotinib in patients with advanced
recurrent and/or metastatic squamous cell cancer of the head and neck (HNSCC). Patients …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With
Recurrent or Metastatic Head and Neck Cancer - PMC Back to Top Skip to main content NIH …

Background We evaluated combined targeting with cetuximab, an anti-epidermal growth
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …

Background Enhanced phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of
rapamycin (mTOR) pathway is one of the key adaptive changes accounting for epidermal …

Purpose: The aim of the study was to evaluate the feasibility and efficacy of adding
bevacizumab and erlotinib to concurrent chemoradiation therapy for first-line treatment of …

The development of epidermal growth factor receptor (EGFR) inhibitors was greeted with
tremendous enthusiasm in the therapy of squamous cell carcinoma of the head and neck …

Squamous cell head and neck cancer (SCCHN) is the seventh most common cause of
cancer death worldwide and its incidence is rising rapidly in developing countries. Despite …